Moderna, Inc.

NASDAQ Global Select
Back to all articles
Very Bullish +85

Why Moderna stock is rocketing today - Finbold

AI-generated analysis

🚀 Moderna stock surged roughly 90% in pre-market trading to briefly hit $120 after positive Phase 3 results for its personalized mRNA cancer vaccine.

✅ The INTerpath-001 trial met its primary endpoint of recurrence-free survival and secondary endpoint of distant metastasis-free survival in high-risk melanoma patients.

🔬 This represents the first successful Phase 3 study of an individualized neoantigen therapy and the first positive Phase 3 result for an mRNA-based cancer treatment.

🤝 The therapy combines Moderna's mRNA platform with Merck's Keytruda to help the immune system identify and destroy cancer cells more effectively.

📅 Regulatory discussions are underway with potential approval expected as early as 2027, validating Moderna's oncology pipeline expansion.

💼 The milestone strengthens Moderna's strategy to diversify revenue beyond its COVID-19 vaccine franchise into the lucrative cancer treatment market.

Bullish Signals
  • Moderna stock surged approximately 90% in pre-market trading, briefly reaching $120, driven by positive Phase 3 trial data for its personalized mRNA cancer vaccine.
  • The INTerpath-001 trial met its primary endpoint of recurrence-free survival and secondary endpoint of distant metastasis-free survival, demonstrating a statistically significant improvement over Keytruda alone in high-risk melanoma patients.
  • This achievement marks the first successful Phase 3 study of an individualized neoantigen therapy and the first positive Phase 3 result for any mRNA-based cancer treatment, validating the company's core technology platform.
  • The trial enrolled over 1,100 patients with high-risk stage IIB to IV melanoma and reported no new safety concerns, reinforcing the safety profile of the combination therapy.
  • Success in this melanoma program validates Moderna's oncology strategy and strengthens its pipeline targeting lung, bladder, and kidney cancers, providing a major new growth driver beyond COVID-19 vaccines.
Full Analysis
Moderna (NASDAQ: MRNA) shares surged approximately 90% in pre-market trading on Wednesday following the announcement of positive Phase 3 clinical trial results for its personalized mRNA-based cancer vaccine, intismeran (mRNA-4157), developed in partnership with Merck. The stock, which had closed the previous session at roughly $63, briefly climbed to $120 as investors reacted to the major milestone. The pivotal data comes from the INTerpath-001 trial evaluating intismeran combined with Merck's Keytruda in patients with high-risk stage IIB to IV melanoma. At an interim analysis of over 1,100 patients who had undergone tumor removal, the treatment combination met its primary endpoint of recurrence-free survival and showed a statistically significant improvement compared to Keytruda alone. Additionally, the study achieved its secondary endpoint for distant metastasis-free survival, indicating a reduced risk of cancer spreading, with no new safety concerns reported. This success marks the first successful Phase 3 study of an individualized neoantigen therapy and the first positive Phase 3 result for any mRNA-based cancer treatment. The therapy utilizes Moderna's platform to create personalized vaccines tailored to unique tumor mutations, enhancing the immune system's ability to destroy cancer cells when paired with Keytruda. With regulatory submissions expected and potential approval as early as 2027, this breakthrough validates Moderna's oncology strategy and offers a significant new growth driver beyond its declining COVID-19 vaccine franchise.